Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Aevis Victoria

BST:G5LN
Snowflake Description

Acceptable track record and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
G5LN
BST
CHF1B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Aevis Victoria SA provides services to healthcare, lifestyle, and infrastructure sectors in Switzerland. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
G5LN Share Price and Events
7 Day Returns
0%
BST:G5LN
-1.4%
DE Healthcare
-0.2%
DE Market
1 Year Returns
-
BST:G5LN
-25.3%
DE Healthcare
-5%
DE Market
G5LN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aevis Victoria (G5LN) 0% 0% -4.3% - - -
DE Healthcare -1.4% 1.8% -6.7% -25.3% -31.8% 14.9%
DE Market -0.2% 6.1% 1.8% -5% 7% 15.7%
1 Year Return vs Industry and Market
  • No trading data on G5LN.
  • No trading data on G5LN.
Price Volatility
G5LN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Aevis Victoria undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Aevis Victoria to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Aevis Victoria.

BST:G5LN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-06-30) in CHF CHF .220000
Payout Ratio Company Filings (2019-06-30) 939.3%
Discount Rate (Cost of Equity) See below 5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:G5LN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.63
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.628 (1 + (1- 18%) (39.54%))
0.808
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.808 * 5.96%)
5.04%

Discounted Cash Flow Calculation for BST:G5LN using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Aevis Victoria is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

BST:G5LN Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= CHF0.22 / (5.04% - 0.23%)
CHF3.55
BST:G5LN Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:G5LN represents 0.8811x of SWX:AEVS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8811x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CHF) x Listing Adjustment Factor
= CHF 4.57 x 0.8811
€4.03
Value per share (EUR) From above. €4.03
Current discount Discount to share price of €11.28
= -1 x (€11.28 - €4.03) / €4.03
-180%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Aevis Victoria is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aevis Victoria's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aevis Victoria's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:G5LN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CHF CHF2.41
SWX:AEVS Share Price ** SWX (2019-06-26) in CHF CHF12.8
Germany Healthcare Industry PE Ratio Median Figure of 9 Publicly-Listed Healthcare Companies 27.24x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 20.2x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aevis Victoria.

BST:G5LN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:AEVS Share Price ÷ EPS (both in CHF)

= 12.8 ÷ 2.41

5.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aevis Victoria is good value based on earnings compared to the DE Healthcare industry average.
  • Aevis Victoria is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Aevis Victoria's expected growth come at a high price?
Raw Data
BST:G5LN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 5.31x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
-21.3%per year
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.05x
Germany Market PEG Ratio Median Figure of 266 Publicly-Listed Companies 1.43x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aevis Victoria, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aevis Victoria's assets?
Raw Data
BST:G5LN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CHF CHF6.57
SWX:AEVS Share Price * SWX (2019-06-26) in CHF CHF12.8
Germany Healthcare Industry PB Ratio Median Figure of 14 Publicly-Listed Healthcare Companies 1.49x
Germany Market PB Ratio Median Figure of 596 Publicly-Listed Companies 1.74x
BST:G5LN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:AEVS Share Price ÷ Book Value per Share (both in CHF)

= 12.8 ÷ 6.57

1.95x

* Primary Listing of Aevis Victoria.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aevis Victoria is overvalued based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess Aevis Victoria's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Aevis Victoria has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Aevis Victoria expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Aevis Victoria, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-21.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aevis Victoria expected to grow at an attractive rate?
  • Aevis Victoria's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Aevis Victoria's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Unable to compare Aevis Victoria's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:G5LN Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:G5LN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts -21.3%
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 10.5%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:G5LN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:G5LN Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
BST:G5LN Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2019-06-30 604 24 187
2019-03-31 591 20 89
2018-12-31 577 16 -9
2018-09-30 572 34 -11
2018-06-30 568 52 -14
2018-03-31 575 56 -7
2017-12-31 583 60 -1
2017-09-30 569 47 4
2017-06-30 556 34 8
2017-03-31 537 45 5
2016-12-31 517 56 2
2016-09-30 513 56 5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aevis Victoria's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if Aevis Victoria is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:G5LN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Aevis Victoria Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:G5LN Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
BST:G5LN Past Financials Data
Date (Data in CHF Millions) EPS *
2019-06-30 2.41
2019-03-31 1.15
2018-12-31 -0.11
2018-09-30 -0.15
2018-06-30 -0.18
2018-03-31 -0.10
2017-12-31 -0.01
2017-09-30 0.05
2017-06-30 0.11
2017-03-31 0.07
2016-12-31 0.03
2016-09-30 0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aevis Victoria will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aevis Victoria's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aevis Victoria has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Aevis Victoria performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aevis Victoria's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aevis Victoria has delivered over 20% year on year earnings growth in the past 5 years.
  • Aevis Victoria has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Aevis Victoria has become profitable in the last year making it difficult to compare the DE Healthcare industry average.
Earnings and Revenue History
Aevis Victoria's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aevis Victoria Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:G5LN Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 603.95 186.57 32.23
2019-03-31 590.54 88.96 29.90
2018-12-31 577.13 -8.66 27.56
2018-09-30 572.48 -11.29 25.99
2018-06-30 567.83 -13.92 24.41
2018-03-31 575.17 -7.42 24.53
2017-12-31 582.51 -0.92 24.64
2017-09-30 569.40 3.63 24.79
2017-06-30 556.29 8.19 24.94
2017-03-31 536.70 5.25 24.41
2016-12-31 517.12 2.31 23.88
2016-09-30 513.26 5.10 24.56
2016-06-30 509.41 7.90 25.25
2016-03-31 508.75 5.83 25.62
2015-12-31 508.09 3.77 25.99
2015-09-30 504.40 3.39 28.73
2015-06-30 500.70 3.02 31.46
2015-03-31 492.78 4.39 27.99
2014-12-31 484.85 5.75 24.53
2014-09-30 464.88 6.16 21.02
2014-06-30 444.92 6.56 17.51
2014-03-31 421.88 7.62 17.51
2013-12-31 398.85 8.68 17.51
2013-09-30 377.60 8.03 14.09
2013-06-30 356.34 7.39 10.67
2013-03-31 331.57 5.36 15.69
2012-12-31 306.79 3.33 20.70
2012-09-30 271.95 1.61 20.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Aevis Victoria has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Aevis Victoria used its assets more efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • Aevis Victoria's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Aevis Victoria's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aevis Victoria has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Aevis Victoria's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aevis Victoria's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aevis Victoria is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aevis Victoria's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Aevis Victoria's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aevis Victoria Company Filings, last reported 2 months ago.

BST:G5LN Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 596.36 397.69 34.53
2019-03-31 596.36 397.69 34.53
2018-12-31 445.03 1,051.94 34.37
2018-09-30 445.03 1,051.94 34.37
2018-06-30 384.43 1,080.90 9.36
2018-03-31 384.43 1,080.90 9.36
2017-12-31 378.16 1,021.86 33.30
2017-09-30 378.16 1,021.86 33.30
2017-06-30 401.32 1,024.18 9.00
2017-03-31 401.32 1,024.18 9.00
2016-12-31 381.50 1,008.60 25.04
2016-09-30 381.50 1,008.60 25.04
2016-06-30 304.90 855.06 8.18
2016-03-31 304.90 855.06 8.18
2015-12-31 300.55 805.42 13.07
2015-09-30 300.55 805.42 13.07
2015-06-30 307.56 747.04 22.62
2015-03-31 307.56 747.04 22.62
2014-12-31 319.20 721.49 48.57
2014-09-30 319.20 721.49 48.57
2014-06-30 318.93 622.49
2014-03-31 318.93 622.49
2013-12-31 232.92 560.87 29.07
2013-09-30 232.92 560.87 29.07
2013-06-30 171.08 352.32
2013-03-31 171.08 352.32
2012-12-31 161.54 407.95 9.80
2012-09-30 161.54 407.95 9.80
  • Aevis Victoria's level of debt (61.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (192.6% vs 61.5% today).
  • Debt is not well covered by operating cash flow (6.5%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 0.8x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Aevis Victoria's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aevis Victoria has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Aevis Victoria's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.72%
Current annual income from Aevis Victoria dividends.
If you bought €2,000 of Aevis Victoria shares you are expected to receive €34 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Aevis Victoria's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.39%).
  • Aevis Victoria's dividend is below the markets top 25% of dividend payers in Germany (3.89%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:G5LN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 335 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.7%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:G5LN Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
BST:G5LN Past Annualized Dividends Data
Date (Data in CHF) Dividend per share (annual) Avg. Yield (%)
2019-03-29 0.220 1.767
2018-03-29 0.110 0.906
2017-03-01 0.110 0.935
2016-06-14 0.110 0.977
2015-04-30 0.110 1.283

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Aevis Victoria has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Aevis Victoria only paid a dividend in the past 4 years.
Current Payout to shareholders
What portion of Aevis Victoria's earnings are paid to the shareholders as a dividend.
  • Dividends paid are thoroughly covered by earnings (11x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aevis Victoria's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.7%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aevis Victoria afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aevis Victoria has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Aevis Victoria's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dino Cauzza
AGE 47
TENURE AS CEO 1.3 years
CEO Bio

Mr. Dino Cauzza has been Chief Executive Officer of Swiss Medical Network at Aevis Victoria SA since May 01, 2018. Mr. Cauzza joined Swiss Medical Network in April 2017 as Delegate of the Board of its subsidiary GSMN Ticino SA, operating Clinica Sant’Anna and Clinica Ars Medica. He benefits of a long experience in the healthcare sector in Switzerland. He worked for many years at Ente Ospedaliero Cantonale (EOC), first as Chief Internal Auditor and then as Chief Financial Officer. He obtained a license in economics (lic. oec. HSG) at the University of St. Gallen and qualified as a chartered accountant. Founder of the consultancy firm Alameda SA, he is also a Board member of several companies, mainly in Ticino.

CEO Compensation
  • Insufficient data for Dino to compare compensation growth.
  • Insufficient data for Dino to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Aevis Victoria management team in years:

1.3
Average Tenure
52.5
Average Age
  • The average tenure for the Aevis Victoria management team is less than 2 years, this suggests a new team.
Management Team

Antoine Hubert

TITLE
Delegate of the Board
COMPENSATION
CHF1M
AGE
53

Gilles Frachon

TITLE
Chief Financial Officer
AGE
69
TENURE
7.3 yrs

Daniel Jandric

TITLE
COO & CEO of Infracore
AGE
42
TENURE
1.3 yrs

Zeynep Berdoz

TITLE
Chief People & Information Officer
AGE
52
TENURE
0.7 yrs

Séverine Van der Schueren

TITLE
Chief Administrative Officer
AGE
49
TENURE
7.2 yrs

Pierre-Olivier Haenni

TITLE
Managing Director
AGE
54
TENURE
6.9 yrs

Dino Cauzza

TITLE
Chief Executive Officer of Swiss Medical Network
AGE
47
TENURE
1.3 yrs

Raouf Finan

TITLE
Chief Executive Officer of Victoria - Jungfrau Collection
AGE
55
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the Aevis Victoria board of directors in years:

9.6
Average Tenure
63.5
Average Age
  • The tenure for the Aevis Victoria board of directors is about average.
Board of Directors

Christian Wenger

TITLE
Chairman of the Board
COMPENSATION
CHF103K
AGE
55
TENURE
7.2 yrs

Raymond Loretan

TITLE
Vice Chairman of the Board
COMPENSATION
CHF600K
AGE
64
TENURE
12.8 yrs

Antoine Hubert

TITLE
Delegate of the Board
COMPENSATION
CHF1M
AGE
53
TENURE
10.3 yrs

Antoine Kohler

TITLE
Non-Executive Director
COMPENSATION
CHF91K
AGE
63
TENURE
11.3 yrs

Cédric George

TITLE
Non-Executive Director
COMPENSATION
CHF53K
AGE
67
TENURE
9 yrs

Michel Reybier

TITLE
Non-Executive Director
COMPENSATION
CHF53K
AGE
74
TENURE
8.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Aevis Victoria's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aevis Victoria has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Aevis Victoria SA provides services to healthcare, lifestyle, and infrastructure sectors in Switzerland. The company operates through Hospitals, Hospitality, Telemedicine, and Real Estate segments. It operates 17 hospitals with 1,111 beds; manages 4 luxury hotels; and owns and rents 47 healthcare and hospitality related real estate properties with a total rentable surface of 216,674 sqm. The company also provides ambulance and day clinic services. In addition, it engages in the aesthetic hospital, patient hotel, real estate management, stem cells, cosmetics, and publishing businesses, as well as organizes seminars. The company was formerly known as AEVIS Holding SA and changed its name to Aevis Victoria SA in June 2015. The company is headquartered in Fribourg, Switzerland. Aevis Victoria SA is a subsidiary of M.R.S.I. Medical Research, Services & Investments S.A.

Details
Name: Aevis Victoria SA
G5LN
Exchange: BST
Founded:
CHF924,580,488
78,576,061
Website: http://www.aevis.com
Address: Aevis Victoria SA
Rue Georges-Jordil 4,
Fribourg,
Fribourg, 1700,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX AEVS Registered Shares SIX Swiss Exchange CH CHF 05. Jul 1999
DB G5L Registered Shares Deutsche Boerse AG DE EUR 05. Jul 1999
BST G5LN Registered Shares Boerse-Stuttgart DE EUR 05. Jul 1999
Number of employees
Current staff
Staff numbers
2,848
Aevis Victoria employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/23 21:31
End of day share price update: 2019/06/26 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/09/13
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.